Review Integrative perspectives on electroacupuncture modulation of vagal–cholinergic and neuro–immune–metabolic regulation in long COVID, 2026, Wang et al.

Chandelier

Senior Member (Voting Rights)
Integrative perspectives on electroacupuncture modulation of vagal–cholinergic and neuro–immune–metabolic regulation in long COVID

Wang, Liwen; Hu, Xiaoyang; Yan, Dongning

Abstract
Long COVID is increasingly recognized as a multisystem condition involving persistent inflammation, autonomic dysregulation, and metabolic disturbance. The vagus nerve–mediated cholinergic anti-inflammatory pathway (CAP) provides a biologically plausible link between neural regulation and immune homeostasis, while metabolic pathways involving AMP-activated protein kinase (AMPK), sirtuin 1 (SIRT1), and peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) are closely related to mitochondrial function and energy balance.

In this review, we synthesize evidence from neuroscience, immunology, and metabolic research to investigate how electroacupuncture (EA) may modulate vagal-cholinergic signaling and the downstream inflammatory and metabolic processes associated with long COVID.

Experimental studies indicate that EA can influence CAP-related mechanisms, including α7 nicotinic acetylcholine receptor (α7nAChR)-mediated inhibition of NF-κB/NLRP3-related inflammatory signaling, and may also regulate AMPK–SIRT1–PGC-1α-associated metabolic pathways. Although clinical evidence is more indirect, it suggests that electroacupuncture may affect autonomic function, inflammatory markers, symptom burden, and neurophysiological regulation.

To support a balanced interpretation, we organize the evidence in this review into a framework based on levels of evidence, which distinguishes direct preclinical findings from indirect clinical indicators and associations used to generate hypotheses. This framework highlights the potential convergence of vagal–cholinergic anti-inflammatory regulation and metabolic recovery pathways, while recognizing that several proposed connections—particularly those linking CAP-related signaling to improvements in long COVID symptoms—require further validation.

Overall, this review provides a structured basis for future mechanistic studies and phenotype-oriented clinical trials evaluating EA as a neuromodulatory strategy for long COVID and related chronic inflammatory conditions.

Web | DOI | PMC | PDF | Frontiers in Integrative Neuroscience | Open Access
 
Back
Top Bottom